Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Top Cited Papers
- 16 July 2009
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 10 (8), 757-763
- https://doi.org/10.1016/s1470-2045(09)70162-7
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Brain Metastases in Patients With Renal Cell Cancer Receiving New Targeted TreatmentJournal of Clinical Oncology, 2008
- Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapyCancer, 2007
- Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a reviewAnnals of Oncology, 2006
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Novel approaches in the therapy of metastatic renal cell carcinomaWorld Journal of Urology, 2005
- Renal cell carcinoma: review of novel single-agent therapeutics and combination regimensAnnals of Oncology, 2005
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000